Search Within

Marc Ladanyi

  1. "Paul Paik"
Formats
  1. Journal Article (27)
  2. Meeting Abstract (20)
Groups
  1. Department of Medicine (47)
  2. Department of Pathology and Laboratory Medicine (47)
  3. GSK Faculty (47)
  4. Human Oncology and Pathogenesis Program (47)
  5. Solid Tumor Oncology Division (47)
  6. Thoracic Oncology (47)

More Groups

People
  1. Paul Paik (47)
  2. Mark Kris (27)
  3. Natasha Rekhtman (27)
  4. Gregory Riely (22)
  5. Charles Rudin (17)
  6. Michael Berger (16)

More People

Years
  1. 2024 (1)
  2. 2023 (3)
  3. 2022 (2)
  4. 2021 (1)
  5. 2020 (3)
  6. 2019 (2)

More Years

Publications
  1. Journal of Clinical Oncology (11)
  2. Journal of Thoracic Oncology (7)
  3. Clinical Cancer Research (6)
  4. Cancer Discovery (3)
  5. JCO Precision Oncology (3)
  6. Cancer (2)

More Publications

Publishers
  1. American Society of Clinical Oncology (14)
  2. American Association for Cancer Research (11)
  3. Elsevier Inc. (7)
  4. Nature Publishing Group (6)
  5. Elsevier Science, Inc. (2)
  6. Nature Research (2)

More Publishers

Results (47)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Microsatellite instability and mismatch repair deficiency define a distinct subset of lung cancers characterized by smoking exposure, high tumor mutational burden, and recurrent somatic MLH1 inactivation
    Journal Article

    Yang, S. R.; Gedvilaite, E.; Ptashkin, R.; Chang, J.; Ziegler, J.; Mata, D. A.; Villafania, L. B.; Nafa, K.; Hechtman, J. F.; Benayed, R.; more...
    Journal of Thoracic Oncology (2024)

    Fulltext@MSK | Save
  • Microsatellite instability defines a subset of lung cancers with smoking exposure, high tumor mutational burden and MLH1 inactivation
    Meeting Abstract

    Yang, S. R.; Gedvilaite, E.; Ptashkin, R.; Chang, J.; Ziegler, J.; Mata, D.; Villafania, L. B.; Nafa, K.; Hechtman, J. F.; Benhamida, J.; more...
    Journal of Thoracic Oncology (2023)

    Fulltext@MSK | Save
  • Targeting NFE2L2/KEAP1 mutations in advanced NSCLC with the TORC1/2 inhibitor TAK-228
    Journal Article

    Paik, P. K.; Fan, P. D.; Qeriqi, B.; Namakydoust, A.; Daly, B.; Ahn, L.; Kim, R.; Plodkowski, A.; Ni, A.; Chang, J.; more...
    Journal of Thoracic Oncology (2023)

    Fulltext@MSK | Save
  • Brief report: Combination of osimertinib and dacomitinib to mitigate primary and acquired resistance in EGFR-mutant lung adenocarcinomas
    Journal Article

    Elkrief, A.; Makhnin, A.; Moses, K. A.; Ahn, L. S.; Preeshagul, I. R.; Iqbal, A. N.; Hayes, S. A.; Plodkowski, A. J.; Paik, P. K.; Ladanyi, M.; more...
    Clinical Cancer Research (2023)

    Fulltext@MSK | Save
  • SRC family kinase inhibition targets YES1 and YAP1 as primary drivers of lung cancer and as mediators of acquired resistance to ALK and epidermal growth factor receptor inhibitors
    Journal Article

    Sato, H.; Kubota, D.; Qiao, H.; Jungbluth, A.; Rekhtman, N.; Schoenfeld, A. J.; Yu, H. A.; Riely, G. J.; Toyooka, S.; Lovly, C. M.; more...
    JCO Precision Oncology (2022)

    Fulltext@MSK | Save
  • Overall survival with circulating tumor DNA-guided therapy in advanced non-small-cell lung cancer
    Journal Article

    Jee, J.; Lebow, E. S.; Yeh, R.; Das, J. P.; Namakydoust, A.; Paik, P. K.; Chaft, J. E.; Jayakumaran, G.; Brannon, A. R.; Benayed, R.; more...
    Nature Medicine (2022)

    Fulltext@MSK | Save
  • Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors
    Journal Article

    Valero, C.; Lee, M.; Hoen, D.; Weiss, K.; Kelly, D. W.; Adusumilli, P. S.; Paik, P. K.; Plitas, G.; Ladanyi, M.; Postow, M. A.; more...
    Nature Communications (2021)

    Fulltext@MSK | Save
  • YES1 amplification as a primary driver of lung tumorigenesis and YES1/YAP1 amplifications as mediators of acquired resistance (AR) to ALK and EGFR tyrosine kinase inhibitors (TKIs)
    Meeting Abstract

    Sato, H.; Kubota, D.; Paik, P. K.; Qiao, H.; Jungbluth, A. A.; Rekhtman, N.; Schoenfeld, A. J.; Yu, H. A.; Riely, G. J.; Lovly, C. M.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • CNS metastases in patients with MET exon 14-altered lung cancers and outcomes with crizotinib
    Journal Article

    Offin, M.; Luo, J.; Guo, R.; Lyo, J. K.; Falcon, C.; Dienstag, J.; Wilkins, O.; Chang, J.; Rudin, C. M.; Riely, G.; more...
    JCO Precision Oncology (2020)

    Fulltext@MSK | Save
  • Tumor analyses reveal squamous transformation and off-target alterations as early resistance mechanisms to first-line osimertinib in EGFR-mutant lung cancer
    Journal Article

    Schoenfeld, A. J.; Chan, J. M.; Kubota, D.; Sato, H.; Rizvi, H.; Daneshbod, Y.; Chang, J. C.; Paik, P. K.; Offin, M.; Arcila, M. E.; more...
    Clinical Cancer Research (2020)

    Fulltext@MSK | Save